Xcovery is seeking partners to launch ensartinib in the United States and globally and to develop vorolanib as the ideal combination partner for an immuno-oncology therapy for various tumor types.
Xcovery is seeking investors who recognize that targeted therapeutics in oncology offer some of the highest values.